Controlled Trial of 3,4 Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS)
Principal Investigator (?)
The main purpose for this study is to provide access to 3,4 DAP, a drug which has demonstrated to be effective in treating weakness associated with Lambert-Eaton Myasthenic Syndrome. LEMS is a rare autoimmune cause of a defect in neuromuscular transmission. The disorder is clinically characterized by fluctuating muscle weakness, hyporeflexia and autonomic dysfunction.
Available at the following location(s)